CD79B p.Cys122Trp
Variant summary
Our verdict is Likely pathogenic. The variant received 6 ACMG points: 6P and 0B. PM2PP3_Strong
The NM_000626.4(CD79B):c.366T>G(p.Cys122Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar. Synonymous variant affecting the same amino acid position (i.e. C122C) has been classified as Benign.
Frequency
Consequence
NM_000626.4 missense
Scores
Clinical Significance
Conservation
Publications
- agammaglobulinemia 6, autosomal recessiveInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, ClinGen
- autosomal agammaglobulinemiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 6 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_000626.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
Ensembl Transcripts
| Sel. | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| CD79B | TSL:1 MANE Select | c.366T>G | p.Cys122Trp | missense | Exon 3 of 6 | ENSP00000006750.4 | P40259-1 | ||
| CD79B | TSL:1 | c.369T>G | p.Cys123Trp | missense | Exon 3 of 6 | ENSP00000376544.3 | P40259-3 | ||
| ENSG00000285947 | c.50-250T>G | intron | N/A | ENSP00000497443.1 | A0A3B3ISS9 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 54
GnomAD4 genome Cov.: 32
ClinVar
Not reported inComputational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
MaxEntScan Visualizer can be used to analyze the impact of this mutation on the neighboring sequence.